Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emmessar Biotech & Nutrition has published its audited Q4 and full-year FY25 results (year ended March 31, 2025) in the Free Press Journal and Nav Shakti newspapers on April 25, 2025, as required under Regulation 47 of SEBI's Listing Regulations. For FY25, revenue from operations rose to Rs. 61.09 lakhs (vs Rs. 55.52 lakhs in FY24) and total income grew to Rs. 261.96 lakhs. Profit before tax improved to Rs. 95.82 lakhs (vs Rs. 81.26 lakhs), but a sharply higher tax expense of Rs. 64.20 lakhs (vs Rs. 16.15 lakhs) pulled net profit down to Rs. 31.61 lakhs from Rs. 65.11 lakhs. Q4 FY25 swung to a net loss of Rs. 6.86 lakhs versus a profit of Rs. 27.00 lakhs in Q4 FY24. Full-year basic EPS was Rs. 0.61 (vs Rs. 1.28). The company operates in three segments: Healthcare, Rent on Leasehold Land, and Others. No investor complaints were pending as of March 31, 2025.
Operating performance improved year-on-year with better topline and pre-tax profit, but a much higher tax bill cut full-year net profit by roughly half and pushed Q4 into a loss, which is likely to be viewed negatively by shareholders despite stable revenue growth.